Prognostic utility of a semiquantitative spinal deformity index

Bone

Volumn 37, Issue 2, 2005, Pages 175-179

  Crans, Gerald G ^a   Genant, Harry K ^b,c   Krege, John H ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF SAN FRANCISCO   (United States)

^c SYNARC INC   (United States)

Author keywords

Osteoporosis; Risk assessment; Spinal deformity index; Vertebral fracture

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PREDICTION; PREVALENCE; PROGNOSIS; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SPINAL DEFORMITY INDEX; VERTEBRA FRACTURE;

AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SPINAL FRACTURES;

EID: 21844431862     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2005.04.003     Document Type: Article

References (11)

1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization. WHO Technical Report Series 843. Geneva: World Health Organization; 1994.
2. J.A. Kanis Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group Osteoporos Int. 4 1994 368 381
3. B.L. Riggs, and L.J. Melton III The worldwide problem of osteoporosis: insights afforded by epidemiology Bone 17 5 Suppl 1995 505S 511S
4. L.J. Melton III, A.W. Lane, C. Cooper, R. Eastell, W.M. O'Fallon, and B.L. Riggs Prevalence and incidence of vertebral deformities Osteoporos Int. 3 1993 113 119
5. N.H. Bjarnason, S. Sarkar, T. Duong, B. Mitlak, P.D. Delmas, and C. Christiansen Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis Osteoporos Int. 12 2001 922 930
6. P.D. Delmas, H.K. Genant, G.G. Crans, J.L. Stock, M. Wong, and E. Siris Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial Bone 33 2003 522 532
7. N.B. Watts, R.G. Josse, R.C. Hamdy, R.A. Hughes, M.D. Manhart, and I. Barton Risedronate prevents new vertebral fractures in postmenopausal women at high risk J. Clin. Endocrinol. Metab. 88 2003 542 549
8. H.K. Genant, C.Y. Wu, C. van Kuijk, and M.C. Nevitt Vertebral fracture assessment using a semiquantitative technique J. Bone Miner. Res. 8 1993 1137 1148
9. B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, and H.K. Genant Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 1999 637 645
10. D. Hosmer, and S. Lemeshow Applied logistic regression 1989 John Wiley and Sons New York, NY 135 149
11. C. Roux, E. Seeman, R. Eastell, J. Adachi, R.D. Jackson, and D. Felsenberg Efficacy of risedronate on clinical vertebral fractures within six months Curr. Med. Res. Opin. 20 4 2004 433 439